A comparative analysis of 11,681 cancer clinical trials conducted in the United States has found a pronounced difference between the kinds of research supported by industry and the kinds backed by federal sponsors. Industry-sponsored trials were more likely to investigate single-agent drug therapies, while federally sponsored studies more often examined interventions that did not rely primarily on medicines, combined several treatment modalities, tested strategies intended to reduce treatment intensity, or focused on rare cancers and pediatric disease. The findings, reported in JAMA Oncology, offer a detailed view of how the source of research funding can shape the questions that reach patients and investigators.
The study addresses a longstanding issue in clinical research: although pharmaceutical companies are essential to the development and testing of new medicines, many important cancer questions extend beyond the evaluation of a single product. Researchers may need to determine whether surgery, radiation, immunotherapy, chemotherapy, targeted treatment, behavioral support, screening, surveillance, or other interventions work best alone or in combination. They may also need to establish whether patients can safely receive less treatment after responding well to initial therapy. Such studies can be clinically important even when they are unlikely to produce a new commercial drug.
The investigators compared trials according to their sponsorship and intervention characteristics. A single-agent drug trial generally evaluates the safety, optimal dose, pharmacokinetics, or therapeutic effectiveness of one principal medicine, sometimes against a placebo or an established standard of care. These studies are central to regulatory approval because they can generate the controlled evidence needed to determine whether a new compound benefits patients. Their concentration among industry-sponsored trials is consistent with the role of pharmaceutical companies in developing and bringing proprietary medicines to market.
Federally sponsored trials showed a broader research profile. They were more likely to study nontreatment interventions, a category that can include prevention, diagnosis, screening, supportive care, follow-up, symptom management, health services, or other approaches not centered on administering an anticancer drug. These interventions may affect outcomes by identifying disease earlier, reducing complications, improving quality of life, or helping patients remain on treatment. They can also address questions involving care delivery and long-term survivorship, areas that may not provide a direct commercial return but can influence the effectiveness and value of cancer care across entire health systems.
Federal studies were also more likely to evaluate multimodality treatment strategies. Cancer therapy frequently depends on the interaction of different approaches: an operation may remove the primary tumor, radiation may target residual disease, and systemic therapy may eliminate cancer cells that have spread elsewhere. Determining the correct sequence, timing, and intensity of these treatments requires trials that are often logistically complex. Such research may involve multiple specialties, long follow-up periods, and comparisons between complete treatment programs rather than between individual drugs. The analysis suggests that public sponsorship plays a particularly important role in supporting this type of coordinated investigation.
Another distinguishing feature of federally sponsored research was a greater emphasis on deescalation. In oncology, deescalation means reducing the amount, duration, or intensity of treatment while preserving the same level of disease control. A trial might test fewer chemotherapy cycles, a smaller radiation dose, less extensive surgery, or the omission of a treatment that appears unnecessary for a biologically defined group of patients. These questions have become increasingly important as survival improves and clinicians pay greater attention to toxic effects, infertility, cardiac injury, secondary cancers, cognitive changes, and other long-term consequences. A therapy that is effective is not automatically optimal if a safer and less burdensome approach can achieve the same outcome.
The study also found that federally sponsored trials were more likely to address rare cancers and childhood cancers. These diseases often present a difficult funding environment because the number of potential participants is small, recruitment can take years, and the commercial market may not be large enough to justify extensive private investment. Pediatric oncology introduces additional scientific and ethical complexities, including differences in drug metabolism, organ development, late effects, and the need to assess how treatment influences growth and lifelong health. Publicly coordinated research can help assemble patients across institutions and preserve studies that would otherwise be too difficult or costly to conduct.
The findings do not mean that one sponsorship model is inherently superior or that industry-supported research lacks clinical value. Drug development depends on industry expertise, manufacturing capacity, regulatory knowledge, and investment. Nor does federal sponsorship guarantee that a trial will be free of limitations or produce a positive result. Instead, the analysis illustrates how the incentives and responsibilities of different sponsors can influence the distribution of research topics. A balanced cancer research ecosystem requires both the testing of new medicines and sustained support for questions involving prevention, treatment combinations, reduced toxicity, rare diseases, children, and the organization of care.
The authors’ comparison may therefore have implications for research policy and funding priorities. If clinical research relies too heavily on commercially attractive questions, important evidence gaps could persist in diseases with small patient populations or in interventions that do not generate a marketable product. Federal agencies, academic institutions, patient organizations, and other nonprofit funders can help fill those gaps by supporting cooperative groups, multisite trials, shared data systems, and studies with long-term follow-up. The analysis provides a quantitative basis for understanding that division of labor and underscores that progress in oncology depends not only on discovering more powerful treatments, but also on determining when, how, and for whom treatment can be delivered more safely and effectively.
Subject of Research: Differences in the focus of industry-sponsored and federally sponsored cancer clinical trials in the United States.
Web References: https://jamanetwork.com/channels/trials
References: Unger JM et al. Comparative study of 11,681 US cancer clinical trials. JAMA Oncology. DOI: 10.1001/jamaoncol.2026.3026.
Keywords: Cancer clinical trials, federal research funding, industry-sponsored research, oncology, drug therapy, multimodality treatment, deescalation, rare cancers, pediatric cancer, clinical research policy.
Tags: Cancer clinical trial fundingchallenges incomparative analysis of U.S. cancer clinical trialsfederal support for rare and pediatric cancer studiesimpact of funding sources on cancer research questionsimportance of non-commercial cancer clinical researchindustry vs federal research in oncologyinfluence of funding on research focus and innovationnon-drug cancer interventions in federally funded studiesrole of industry-sponsored drug therapy trialsshaping patient treatment options through fundingtreatment combination strategies in cancer researchtypes of cancer treatments studied in clinical trials
